Technical Analysis for CYCC - Cyclacel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.42 -4.11% -0.02
CYCC closed down 4.11 percent on Friday, September 13, 2019, on 20 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CYCC trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Boomer Sell Setup Bearish Swing Setup -4.11%
20 DMA Support Bullish -4.11%
Narrow Range Bar Range Contraction -4.11%

Older signals for CYCC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Serious Diseases Autoimmune And Inflammatory Diseases Cyclacel Treatment Of Autoimmune And Inflammatory Diseases Dna Synthesis PLK1 Cdk Inhibitor Cell Cycle Cell Cycle Checkpoint Cyclin Dependent Kinase Cyclin Dependent Kinase 2 E Human Cancers M Checkpoint Sapacitabine Seliciclib
Is CYCC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.73
52 Week Low 0.2813
Average Volume 76,817
200-Day Moving Average 0.68
50-Day Moving Average 0.4996
20-Day Moving Average 0.4248
10-Day Moving Average 0.4127
Average True Range 0.0457
ADX 30.15
+DI 13.9324
-DI 26.4089
Chandelier Exit (Long, 3 ATRs ) 0.4129
Chandelier Exit (Short, 3 ATRs ) 0.4871
Upper Bollinger Band 0.4886
Lower Bollinger Band 0.361
Percent B (%b) 0.46
BandWidth 30.037665
MACD Line -0.0215
MACD Signal Line -0.029
MACD Histogram 0.0075
Fundamentals Value
Market Cap 4.79 Million
Num Shares 11.4 Million
EPS -4.18
Price-to-Earnings (P/E) Ratio -0.10
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.45
Resistance 3 (R3) 0.45 0.45 0.44
Resistance 2 (R2) 0.45 0.44 0.44 0.44
Resistance 1 (R1) 0.43 0.43 0.43 0.43 0.44
Pivot Point 0.43 0.43 0.42 0.42 0.43
Support 1 (S1) 0.41 0.42 0.41 0.41 0.40
Support 2 (S2) 0.41 0.41 0.41 0.40
Support 3 (S3) 0.39 0.41 0.40
Support 4 (S4) 0.39